This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Sokoloff, B. Articles by Relos, H. Search for Related Content PubMed PubMed Citation Articles by Sokoloff, B. Articles by Relos, H.

Ascorbic Acid Analog in Experimental Cancer^*

( Southern Bio-Research Laboratory, Florida Southern College, Lakeland, Fla.)

When D-glucoascorbic acid was added to a Sherman-LaMer scorbutogenic diet at a level of 1 or 2 per cent, no apparent toxic effects such as diarrhea, alopecia, or hemorrhagia in rats and mice was produced, but on this diet the ascorbic acid concentrations of the blood plasma and certain tissues were lowered to nearly zero in 20 days.

Intraperitoneal injection of 250 mg/kg/day of D-glucoascorbic acid for 7 days did not retard the growth of mouse Sarcoma 180 and only slightly inhibited the Crocker rat carcinoma and mouse adenocarcinoma E 0771.

Continuous feeding of a Sherman-LaMer ration containing 1 or 2 per cent of D-glucoascorbic acid for 4 weeks considerably retarded the Crocker carcinoma and adenocarcinoma E 0771.

D-Glucoascorbic acid did not affect the growth of liposarcoma in guinea pigs receiving an adequate supply of vitamin C, although the tumor growth was retarded considerably in scorbutic guinea pigs.

In the absence of dietary ascorbic acid, the urinary excretion of the citrovorum factor in rats was decreased by a diet containing 1 or 2 per cent of the analog, but the antagonist did not significantly affect CF excretion in the presence of dietary ascorbic acid.

^* Presented before the annual meeting of the American Association for Cancer Research, New York City, April 11–13, 1952 (abstracts published in Cancer Research, 12:284, 298, 1952) and the annual meeting of the American Society for Experimental Pathology, April 15, 1952 (abstracts published in Fed. Proc., 11:427, 428, 1952).

Aided by grant from Damon Runyon Fund for Cancer Research.

Received 1/ 2/53.